Materialise (NasdaqGS:MTLS) Stock Dips As Higher EBIT Meets Soft Software Demand

Materialise came into this earnings print with the stock quietly up double digits over the past month. The 3D printing specialist then dropped 5.4% on the day, even as Q2 told a cleaner story of profits and cash.

Revenue reached €70.1m with adjusted EBIT of €3.9m, and management lifted full year EBIT guidance to a range of €12m to €14m. Strong free cash flow and a net cash position of €74.2m add weight to that upgrade. The gap between the softer share price and firmer profitability is where the real story starts.

Is Materialise trading at a genuine discount on a 26.7x trailing P/E, or is the softer revenue outlook already fairly captured in the share price? Compare the current market implied expectations with the valuation analysis for Materialise

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: €70.1m vs. €64.8m (up about 8%)
• Net Income, Q2 2026 vs. Q2 2025: €3.3m vs. €0.2m (very large increase with a much stronger profit contribution)
• Basic EPS, Q2 2026 vs. Q2 2025: €0.057 vs. €0.003 (very large increase per share in line with higher earnings)
• Adjusted EBIT Margin, Q2 2026: 5.5% on revenue of €70.1m, supported by a gross margin of 56.8% and positive free cash flow

Prefer clean charts instead of another wall of earnings tables and footnotes? See Materialise’s full financial picture, with a clear view of its valuation in our company report for Materialise.

Materialise hits key proof points in medical and series manufacturing

Bulls argue that Materialise can shift its mix toward higher value medical, software and series manufacturing work that supports stronger margins and cash. Q2 results partially back that up. Medical now accounts for 53% of revenue, with Devices & Services up 19% year on year and segment adjusted EBITDA at €11.6m on a 31% margin. That is exactly the type of clinically integrated, higher value activity the thesis expects from new implants and planning tools.

On the industrial side, Manufacturing revenue grew around 7%, with aerospace up 40% and H1 segment EBITDA roughly breakeven. That supports the idea of more repeatable series manufacturing volumes. Portfolio focus is also visible through the RapidFit and Eyewear divestments. The missing piece for the bullish narrative is Software, where revenue fell 3% and Q2 profitability softened even though recurring revenue reached 86% and CO AM launches are on track.

Compare whether this mix shift in higher margin medical work and series manufacturing is changing the story for institutional investors. See the consensus price target analysis for Materialise

Materialise bears still see unproven software and divestment upside

The key bearish claim around Materialise is that softer software demand, long lead times on partnerships and divestments that dilute revenue will cap progress even if Medical holds up. Q2 results give that view some backing. Software revenue fell 3% with elongated sales cycles and weaker U.S. academic budgets, and adjusted EBITDA in the segment eased to €1m despite 86% recurring revenue and the CO AM Pro launch. That is a clear milestone missed for a business expected to be a higher margin growth engine.

Bears also worry that asset sales could leave a revenue hole that Medical and Manufacturing will struggle to fill. Group revenue growth in H1 was about 4% and full year guidance is only reaffirmed rather than raised, even after RapidFit and Eyewear divestments. EBIT guidance has improved, but the mix of cost control and slower top line progress keeps the bearish focus on execution risk rather than removing it.

With EBIT guidance now higher but revenue growth still modest and the Materialise share price down 5.4% on the latest close, check whether the cash and balance sheet genuinely support this earnings story in our financial health analysis of Materialise stock.

Stay Ahead With Simply Wall St

If Materialise’s stronger EBIT guidance, cash position and recent share price pullback have caught your attention, register for free with Simply Wall St and add it to a Watchlist to track price moves against fair value and watch for a potential entry point. Once you own the stock, use the Portfolio Command Center to keep your holdings organised and surface only the most important, timely updates that matter. For a broader view on what other investors are seeing in Materialise and similar stocks, join the conversation through the Community. That way you can spot hidden catalysts or emerging risks early and stay a step ahead of the wider market.

Seeking Alternatives Beyond Materialise?

Fresh ideas can move quickly. Some stocks are building quiet breakout momentum while they are still under the radar for now. Scan these curated lists before the crowd and act now.

• Spot companies with strong balance sheets that could hold up when sentiment shifts by reviewing the curated list of solid balance sheet and fundamentals stocks (51 results). Consider researching these opportunities before broader attention arrives.
• Explore potential AI-related opportunities by scanning the hand picked 74 profitable AI stocks that aren't just burning cash. These are businesses already generating cash, not just burning it.
• Identify possible income pillars for a portfolio that aims for yield and resilience by checking the curated 12 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com